1	<b>Functional Characte</b>	erization of Lipid Regulatory Effects of Three Genes				
2		Using Knockout Mouse Models				
3						
4						
5 6	Chen Yao <sup>1,2</sup> , Holly Savage <sup>3</sup> , David E Hill <sup>4,5</sup> , Marc Vidal <sup>4,</sup>	Tong Hao <sup>4,5</sup> , Gha Young Lee <sup>1,2</sup> , Yuka Takemon <sup>3</sup> , Wenting Bian <sup>4,5</sup> , <sup>5</sup> , Ron Korstanje <sup>3*</sup> and Daniel Levy <sup>1,2*</sup>				
7						
8	<sup>1</sup> The Framingham Heart Stud	dy, Framingham, MA;				
9	<sup>2</sup> The Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and					
10	Blood Institute, Bethesda, MD;					
11	<sup>3</sup> The Jackson Laboratory, Ba	ur Harbor, ME;				
12	*Center for Cancer Systems Biology (CCSB) and Dept. of Cancer Biology, Dana-Farber Cancer					
13	Institute, Boston MA, USA;	Dept. of Genetics, Blavatnik Institute, Harvard Medical School,				
14 15	Boston MA					
16	*Corresponding author:	Daniel Levy, MD				
17		Email: levyd@nih.gov				
18						
19						
~ ~						
20						
21						
22						
23						
24						

#### 25 Abstract:

Integrative analysis that combines genome-wide association data with expression quantitative trait analysis and network representation may illuminate causal relationships between genes and diseases. To identify causal lipid genes, we utilized genotype, gene expression, protein-protein interaction networks, and phenotype data from 5,257 Framingham Heart Study participants and performed Mendelian randomization to investigate possible mechanistic explanations for observed associations. We selected three putatively causal candidate genes (ABCA6, ALDH2, and SIDT2) for lipid traits (LDL cholesterol, HDL cholesterol and triglycerides) in humans and conducted mouse knockout studies for each gene to confirm its causal effect on the corresponding lipid trait. We conducted the RNA-seq from mouse livers to explore transcriptome-wide alterations after knocking out the target genes. Our work builds upon a lipid-related gene network and expands upon it by including protein-protein interactions. These resources, along with the innovative combination of emerging analytical techniques, provide a groundwork upon which future studies can be designed to more fully understand genetic contributions to cardiovascular diseases. 

## 61 Introduction

Cardiovascular disease (CVD) remains the leading cause of death worldwide<sup>1</sup>. A key goal of CVD 62 research is the identification of specific genes and genetic variants that contribute to the disease<sup>2</sup>. 63 Genome-wide association studies (GWAS) have revealed numerous inherited DNA sequence 64 variants associated with CVD and its risk factors<sup>3-5</sup>. For many known CVD-associated variants, 65 however, the biological mechanisms and underlying causal genes remain largely unknown. The 66 overwhelming majority of CVD-related genetic variants lie within intergenic or noncoding regions 67 of the genome <sup>3</sup>, indicating that these single nucleotide polymorphisms (SNPs) impact CVD risk 68 indirectly, for example, by altering transcription levels of nearby (cis) or remote (trans) genes. The 69 identification of genetic variants that alter gene expression – expression quantitative trait loci 70 (eQTLs) – has paved the way for functional studies linking candidate genes to disease<sup>6</sup>. 71

We postulated *a priori* that a network approach could portray biological systems underlying 72 CVD traits and provide insights into disease-related genes and pathways. Network-based 73 74 approaches have many biological and clinical applications and have yielded promising results in recent studies<sup>7, 8</sup>. Not only do networks allow for the integration of different types of biological 75 information, but they also allow for unbiased discovery of disease genes that, when integrated with 76 protein-protein interactions (PPI), can provide mechanistic explanations for diseases<sup>9</sup>. In a 77 previous study, we linked 21 CVD traits based on their shared SNP associations, and in doing so, 78 recapitulated the clustering of metabolic risk factors observed in epidemiological studies <sup>10</sup>. Here, 79 we expand that network model to identify causal genes and pathways for lipid traits and tested 80 three genes for causality. 81

By integrating high-quality PPI data<sup>11</sup> with SNPs associated in GWAS of lipids, gene 82 expression, and fasting blood lipid levels in 5,257 Framingham Heart Study (FHS) participants 83 (Supplementary table 1), we selected ABCA6, ALDH2, and SIDT2 as candidate causal genes for 84 85 lipid traits (low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides (TG)). Dysregulation of circulating lipid levels has been implicated in the 86 pathogenesis of CVD<sup>12</sup>. To confirm that the candidate genes identified from the network model 87 are causal for the corresponding lipid traits, we created mouse knockout (KO) models to assess, in 88 89 vivo, the consequences of perturbing key genes as well as the networks in which they function. The mouse KO models were therefore phenotyped for the corresponding lipid traits and 90 additionally liver gene expression was measured by RNA-Seq to study perturbations within the 91 92 network (Figure 1).

We posit that creating a network based on the relationships among genes, traits, and PPIs can further our understanding of the genetic basis of lipid traits and their contributions to lipid dysregulation. By combining human genotype data with mouse KO experiments, we also provide a framework for selecting and validating lipid-related candidate genes.

## 97 **Results**

## 98 Identifying lipid trait-related expression quantitative loci

We identified 4670 (84%) lipid trait-associated expression quantitative loci (eQTLs; SNPs association with gene expression) by linking 5568 lipid trait GWAS SNPs (Supplementary Table 2) that were also associated with gene expression in whole blood in 5,257 Framingham participants<sup>13</sup> (Supplementary Table 3). Seventy-two percent of these eQTLs affected the expression of a nearby (*cis*) transcript (SNP located within 1 Mb of the transcript), suggesting that

they may play a role in regulating gene expression. For these eQTLs, we conducted mediation testing to detect if the association of the GWAS SNP with the corresponding trait was mediated by gene expression. At P<0.005, we identified 464 SNPs with significant mediation effects on

107 lipids traits (Supplementary Table 4).

## 108 Expanding the candidate gene network

To expand the candidate gene network, we built a CVD gene network by incorporating all protein 109 coding genes containing CVD GWAS SNPs. Our CVD-centric network contained binary PPIs for 110 846 CVD-associated proteins (out of ~1,300 tested) extracted from a dataset of ~58,000 binary 111 PPIs among 10,690 human proteins obtained from both systematic binary mapping and literature 112 curations<sup>14</sup>. The 846 CVD-associated proteins and their first-degree neighbors constituted a 113 network of ~8,600 interactions among 4,336 proteins (Supplementary Table 5), including 444 114 intra-CVD PPIs among 349 lipids-associated proteins (Supplementary Table 6). This expanded 115 network is amenable to investigating disease models by analyzing other features such as shared 116 gene ontology (GO) terms, shared expression profiles, and functional similarity. 117

## 118 *Ranking candidate genes*

Combining GWAS lipid trait SNPs, eQTLs, and mediation results, we selected seven candidate 119 genes to test against three lipid traits in Mendelian randomization (MR) analyses: DOCK7, 120 TAGLN, SIDT2, ALDH2, SLC44A4, ABCA6, and ATG4C (See Methods for gene selection). We 121 used genetic variants (focusing on those that are eQTLs variants) as instruments to investigate the 122 causal relations between gene expression and lipid phenotypes. The causal effects of the seven 123 124 genes were further tested by MR using independent GWAS data from the Global Lipids Genetics Consortium (GLGL)<sup>15</sup> (Table 1) and filtered based on 1) gene novelty (not previously studied in a 125 mouse model for cardiovascular phenotypes), 2) repository availability of knockout sperm or 126 embryos that have been shown to produce viable animals, and 3) interaction with CVD-related 127 proteins in an integrated network based on PPIs. This approach identified three genes as suitable 128 for detailed mouse KO experiments: ABCA6 for non-HDL, ALDH2 for HDL, and SIDT2 for TG 129 (Table 2). Though ABCA6 was not found to be causally associated with lipids traits by MR. 130 rs740516, a variant in ABCA6, was significantly associated with LDL in GWAS (P=7x10<sup>-9</sup>) and 131 was associated with expression of ABCA6 ( $P=3.3x10^{-5}$ ). SIDT2 has been previously studied in 132 relation to lipid metabolism and homeostasis, our finding is one of the first to utilize an integrative 133 genomics framework to better understand the genetic basis of its effect on lipid traits<sup>16, 17</sup>. The 134 effects of these genes on secondary lipid traits (ABCA6 on HDL and TG, ALDH2 on non-HDL and 135 TG, SIDT2 on HDL and non-HDL) are also summarized. 136

# 137 ABCA6, ALDH2, SIDT2, and the corresponding mouse knockout models

138 *ABCA6* Knockout

The protein ABCA6, encoded by *ABCA6*, is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various substrates, including lipids, peptides, vitamins, and ions<sup>18</sup>, across extra- and intracellular membranes. *ABCA6* is expressed exclusively in multicellular eukaryotes and has been suspected of acting as an intracellular transporter in macrophage lipid homeostasis<sup>19</sup>.

144 Comparing total cholesterol and non-HDL cholesterol levels (which are primarily comprised of 145 LDL cholesterol) between C57BL/6N-*Abca6*<sup>tm2a(KOMP)Wtsi</sup>/TcpRkorJ mice (*Abca6* knockout) and 146 WT C57BL/6N mice, we observed a significant increase in total cholesterol in males on the chow

147 diet at 22 weeks of age and in males on the high-fat diet at both 18 and 22 weeks of age (Figure148 2). A similar trend was identified in females.

In addition, knockout of *ABCA6* led to a significant increase in HDL cholesterol in male mice on the chow diet but not on a high-fat diet with a similar but nonsignificant trend observed in females. This finding is supported by previous studies that have shown that *ABCA6* is involved in reverse cholesterol transport, specifically by facilitating phospholipid and cholesterol export from the cell<sup>19, 20</sup>. There were no significant differences in TG levels in the female mice on both chow

- and high-fat diet, but the male  $Abca6^{-/-}$  mice had lower TG levels on the chow diet.
- 155 *ALDH2* Knockout

*ALDH2* encodes aldehyde dehydrogenase, the second enzyme of the major oxidative pathway of alcohol metabolism. This gene encodes a mitochondrial isoform, which has a high affinity for acetaldehydes and is localized in the mitochondrial matrix. Deficiencies in *ALDH2* have been shown to be correlated with differences in lipid levels due to its role in the metabolism of lipidperoxidation-derived aldehydes <sup>21</sup>.

161 ALDH2 was causally related to all three lipids in MR (Table 1). In addition, SNPs in ALDH2 were significantly associated with HDL and LDL in GWAS and gene expression in FHS 162 (Supplementary Table 3). Comparing HDL cholesterol levels between B6Dnk;B6N-163 Aldh2tm1a(EUCOMM)Wtsi/IegRkorJ mice (Aldh2 knockout) and WT C57BL/6N mice, we found 164 significantly increased HDL cholesterol levels in both female and male Aldh2 KO mice at several 165 time points compared to controls when fed the chow diet (Figure 3). On a high-fat diet, we no 166 167 longer observed a difference in males, but there was a significant difference in females at 18 weeks of age. 168

Except for a few specific time points, there were no differences in non-HDL levels for either diet in males or females. There were no differences in TG levels in the female mice, but in the male mice we observed increased TG levels in the KO animals on a high-fat diet. This suggests that the knockout of *Aldh2* in males might lead to a decreased risk of CVD on the chow diet, but an increased risk on the high-fat diet.

174 SIDT2 Knockout

SIDT2 is a transmembrane protein that predominantly localizes on lysosomes but is also detectable 175 176 in the plasma membrane of human embryonic kidney cells. Overexpression of SIDT2 in some cells is accompanied by a significant reduction of detectable lysosomes, indicating that the 177 overexpressed protein leads to lysosomal dysfunction. Lysosomes are thought to be the major 178 intracellular compartment for the degradation of macromolecules and play an important role in 179 regulating lipid degradation pathways<sup>22, 23</sup>. Previous *SIDT2*-knockout experimentation has shown 180 that SIDT2 plays a major role in regulating lipid autophagy and metabolism and cholesterol and 181 triglyceride transport in mammalian cells, particularly in the liver<sup>16, 17</sup>. 182

*SIDT2* was significant in MR test for all three lipids traits. SNPs in *SIDT2* were significantly associated with LDL in GWAS and gene expression in FHS (Supplementary Table 3). We identified *SIDT2* in our human cohort to be associated primarily with triglycerides and therefore compared TG levels between B6;129S5-*Sidt2<sup>tm1Lex/</sup>*MmucdRkorJ mice (*Sidt2* knockout) and WT control littermates. We observed a significant increase in TG levels in the female mice on the chow

diet at 18 and 22 weeks of age (Figure 4). Male TG levels were only increased at 8 weeks of age.

In addition, HDL cholesterol levels were significantly decreased in male and female KO mice on the high-fat diet. On a chow diet, HDL cholesterol levels appeared to decrease even further in male mice. HDL cholesterol levels, however, increased slightly in females. Female non-HDL cholesterol levels did not change on the chow diet; in the early stages there was a large decrease in non-HDL cholesterol on the high-fat diet that ultimately dissipated. Male non-HDL cholesterol levels did not change on the high-fat diet and significantly increased on a chow diet.

## 195 Expression changes after gene knock out

To explore transcriptome-wide alterations resulting from knocking out the target genes, we 196 conducted RNA-Seq for ALDH2 and ABCA6 in three male and three female knockout animals and 197 three male and three female control littermates for each of the two diets. We didn't conduct the 198 RNA-Seq for SIDT2 in light of previously reported studies of this knockout <sup>16, 17</sup>. At FDR<0.05 (T 199 test, P<0.014), we identified an average of 238 differentially-expressed genes (ranging from 69 to 200 403 for eight comparisons) after knockout (Supplementary Table 7). The differentially-expressed 201 genes were analyzed through the use of Ingenuity Pathway Analysis (IPA,QIAGEN Inc.,)<sup>24</sup>. 202 Function enrichment analyses were conducted on the differentially expressed genes using curated 203 information from the QIAGEN Knowledge Base<sup>24</sup>. Though canonical pathways of differentially 204 expressed genes from mice of different diet conditions are enriched in different metabolic and cell 205 signaling pathways, the affected diseases and molecular functions are highly consistent with regard 206 to metabolic disease and lipid metabolism (Supplementary figure 1). The top toxicological 207 functions were liver steatosis and cardiac dysfunction. Network analysis based on Ingenuity 208 Knowledge Base<sup>24</sup> revealed that Abca6 affected cholesterol level via cytokine IFNG (interferon 209 gamma) and that Aldh2 affected cholesterol level through enzyme GNMT (glycine N-210 211 methyltransferase) and acetaldehyde (Supplementary Figure 2). Comparing RNA-seq data from Abca6 and Aldh2 knockout of the same sex and diet, we found 19%-60% overlap of differentially 212 expressed genes. Using IPA functional enrichment at P<0.005, we found that the overlapping 213 214 genes are enriched in lipid metabolism (Supplementary Table 8), suggesting a common pathway 215 affected by these two very different genes.

## 216 **Discussion**

To represent the complex molecular dynamics that underlie CVD, we constructed a network that

218 integrates SNPs, gene expression, protein-protein interactions, and lipid phenotypes. From this

integrated network approach, we identified three genes -ABCA6, ALDH2, and SIDT2 - that were

220 linked to lipid levels and were investigated further through mouse knockout models. The mouse

221 experiments recapitulated network-predicted relations of all three genes to the corresponding lipid

traits and provided experimental support for the integrative approach we developed.

Disease processes involve many interacting molecules and physical and biochemical processes, and thus the analysis of single data types is often insufficient to explain the etiology of complex traits. For example, carriers of risk alleles do not always have phenotypic consequences as such genetic variants do not necessarily alter the expression of disease-related genes or proteins. Therefore, in order to draw a more comprehensive view of biological processes, high-throughput data from different elements of multidimensional molecular information must be integrated and analyzed.

Results from our mouse knockout models provide proof of principle for the utility of the
 integrative network approach that we developed. Results of the mouse experiments largely support
 our network model, with a few exceptions. Knockout of *Abca6*, which contains GWAS SNPs for

LDL cholesterol and total cholesterol, resulted in higher total cholesterol (which is largely LDL 233 cholesterol) and HDL cholesterol in male mice, suggesting a potential role of this gene in CVD 234 development. ABCA6 plays a key role in macrophage lipid homeostasis by facilitating 235 phospholipid and cholesterol export from the cell<sup>19, 20</sup>. ABCA6 dysfunction may cause a buildup 236 of intracellular phospholipids and cholesterol. Knockout of Aldh2, which was chosen for its 237 putatively causal association with HDL cholesterol, resulted in significantly increased HDL 238 cholesterol levels in both female and male mice. Aldehyde dehydrogenase, the protein encoded by 239 ALDH2, is an enzyme in the oxidative pathway and plays a major role the metabolism of lipid 240 peroxidation-derived aldehydes<sup>21</sup>. In our knockout models, the absence of *Aldh2* resulted in higher 241 lipid levels, which supports the idea that ALDH2 is involved in lipid degradation/clearance. 242 Knockout of Sidt2, which contains GWAS SNPs for HDL cholesterol, resulted in a significant 243 increase in triglyceride levels in the females on the chow diet at 18 and 22 weeks of age. SIDT2 244 plays a crucial role in the uptake and intracellular transport of triglycerides and cholesterol <sup>22, 23</sup>. 245 Previous studies<sup>16</sup> have shown that the absence of *Sidt2* causes increased serum triglycerides and 246 free fatty acids in mice. After analyzing the knockout results, we compared them with expression 247 data for the corresponding human genes. We discovered that while each gene knockout produced 248 249 some significantly different results in the female and male mice, FHS human gene expression data did not reveal sex differences in lipid effects for any of the genes (P>0.05, data not shown). This 250 may be due to innate differences in lipid metabolism and regulation between the two species. 251

In contrast to similar studies that have relied on public databases to identify eOTLs<sup>25</sup>, our study 252 takes a direct and thorough approach, analyzing extensive phenotypic datasets in relation to gene 253 expression in human peripheral blood. This method, combined with mediation analysis, allowed 254 us not only to identify significant pathway enrichment from GWAS SNPs, but also to investigate 255 mechanisms underlying lipids traits. Our study is also unique in that we combined several 256 257 emerging techniques to identify and validate genes; these techniques included the use of functional eQTL studies and the integration of PPI data. Functional studies, especially those involving the 258 use of networks to mirror biological systems, have shown great promise in the ability to identify 259 candidate genes for various diseases<sup>26</sup>. In one study, Atanasovska et. al used a network-based 260 approach to prioritize genes for hundreds of cardiometabolic SNPs to identify disease-predisposing 261 genes<sup>27</sup>. The integration of PPI with eOTL analyses also has great potential to offer mechanistic 262 explanations for diseases<sup>11, 14</sup>. 263

One limitation of our study is the use of whole blood for expression profiling. Although the lipid 264 265 traits were measured in blood, and as such, whole blood-derived eQTLs may be highly relevant to the phenotypes we studied, in some cases, we observed opposite direction between MR predicted 266 effects and mouse knockout (ALDH2 on HDL). Another limitation is that our MR analyses could 267 not infer sex-specific causal effects because the underlying GWAS studies were conducted in 268 pooled-sex analyses, even though our mouse experiments revealed notable sex differences. 269 Differential lipid metabolic responses between male and female mice have also been previously 270 271 identified in other gene knockout studies<sup>28</sup>.

In summary, our network approach allowed us to identify novel candidate genes that may contribute to CVD via lipid effects. As such, these genes represent attractive targets for the treatment of dyslipidemia and the prevention of CVD. Looking forward, we plan to continue to expand the CVD network and investigate additional causal genes. As we do so, we anticipate that it will increasingly explain genes, pathways, and mechanisms underlying CVD and point toward promising precision drug targets. Our integrative network also provides insights into how

dysfunction of novel CVD-associate genes is manifested at the molecular level <sup>29</sup>. Approaches 278 279 similar to those used in this study may not only be expanded upon in relation to CVD but also be used to investigate other diseases impacted by genetic and epigenetic factors. To make future 280 281 studies more comprehensive and accurate, it will be important to expand eQTL databases to other disease-related tissues and to include additional clinically important traits as well. 282

#### 283 **Materials and Methods**

#### **Samples and Phenotypes** 284

In 1948, the FHS started recruiting participants (original cohort) from Framingham, MA to begin 285 the first round of extensive physical examinations and lifestyle surveys to investigate CVD and its 286 risk factors <sup>30</sup>. In 1971 and 2002, the FHS recruited offspring (and their spouses) and adult 287 grandchildren of the original cohort participants into the offspring and third-generation cohorts, 288 respectively <sup>31-33</sup>. Plasma total cholesterol, HDL cholesterol, triglycerides, and glucose were 289 290 measured in the morning after an eight-hour overnight fasting. Body mass index (BMI) was defined as weight (kilograms) divided by height squared (meters<sup>2</sup>). Current smokers were defined 291 as those who smoked, on average, at least one cigarette per day during the year prior to the FHS 292 293 clinical assessment. Clinical characteristics of the study sample are summarized in Supplementary Table 1. All participants from the FHS gave informed consent for participation in this study and 294 for the collection of plasma and DNA for analysis. The FHS study protocol was approved by 295 296 Boston Medical Center: Protocol ID: H-27984, Boston University Medical Center IRB (BUMC

- IRB) Title: FRAMINGHAM HEART STUDY BIOMARKER PROJECT. 297
- 298 Genotype data: 5,568 SNPs that were associated with the three lipid traits – HDL cholesterol, LDL cholesterol, and triglycerides – at  $p \le 5 \times 10^{-8}$  (in the GRASP database, downloaded in June 2016, 299
- Supplementary Table 2) were curated and matched with the FHS 1000 Genomes Project imputed 300
- genotype data <sup>34</sup>. SNPs with imputed quality score  $(r^2) < 0.3$  and minor allele frequency (MAF) 301 <0.01 were excluded, resulting in 4173 genome-wide significant SNPs for eQTL analysis.
- 302

Gene expression: Whole blood was collected in PAXgene<sup>™</sup> tubes (PreAnalytiX, Hombrechtikon, 303

- Switzerland) and frozen at -80°C. RNA was extracted using a whole blood RNA System Kit 304 (Qiagen, Venlo, Netherlands) and mRNA expression profiling was assessed using the Affymetrix 305
- 306 Human Exon 1.0 ST GeneChip platform (Affymetrix Inc, Santa Clara, CA), which contains more
- than 5.5 million probes targeting the expression of 17,873 genes. The Robust Multi-array Average 307
- (RMA) package<sup>35</sup> was used to normalize the gene expression values and remove any technical or 308
- spurious background variation. Linear regression models were used to adjust for technical 309
- covariates (batch, first principal component, and residual mean of all probesets). 310

#### Identification of LIPIDS-associated eQTLs 311

The eQTLs were identified from FHS genotype data and whole blood gene expression as described 312 313 previously <sup>13</sup>. eQTL analyses were conducted in two phases: 1) gene expression residuals were generated after accounting for the effects of sex, age, platelet count, white blood cell count, and 314 315 imputed differential blood cell counts; analyses were performed using R version 3.0.1 with a mixed-effect modeling package that adjusted for familial relationships; and 2) underlying 316 317 confounding factors were accounted for by 20 Probabilistic Estimation of Expression Residuals (PEERs)<sup>36</sup> factors that were computed using the residualized expression data. The residualized 318 expression was fit to a linear model using the PEER factors along with sex, age, and effect allele 319 dosages. The algorithm was implemented with Graphical Processing Units (GPUs). cis-eQTLs 320

were defined as SNPs that reside within 1 Mb up or downstream of the transcription start site.
 False discovery rate (FDR) computations for *cis*- and *trans*-eQTLs were computed separately.
 SNPs at FDR <0.05 were considered statistically significant eQTLs.</li>

Putative causality was first tested by mediation tests, in which the underlying mechanism for a 324 relationship between two variables is tested by introducing a third explanatory variable. The 325 analysis was conducted with the Mediation Package<sup>37</sup> in R where the "exposure" variable 326 represented a SNP, the "mediator" or "explanatory variable" represented gene expression, and the 327 "outcome" variable represented the phenotype. The mediation effect was measured on a scale from 328 0-100% where a 100% mediation effect indicated that the entire relationship between a SNP and 329 a phenotype (direct effect) was explained by changes in gene expression, i.e., the "mediator" or 330 the "explanatory variable." Significant mediation effects were selected at a permutation p-value 331 <0.005 (based on 1000 permutations). 332

Significant mediation effects were further tested by Mendelian randomization (MR)<sup>38</sup> to 333 334 determine causal associations between gene expression and phenotype. MR uses common genetic variants with well-understood effects on an exposure as instrumental variables (IV) to infer 335 causality of an exposure to an outcome. This approach was applied to the aforementioned three 336 lipid traits (LDL cholesterol, HDL cholesterol, and triglycerides). Here, the sentinel cis-eQTL (top 337 eQTL located within 1 Mb of the tested gene), based on the lowest SNP-gene expression p-value 338 from the 1000G GWAS, was selected as the IV for its corresponding gene in MR analysis. Based 339 on the association between the sentinel *cis*-eOTL and the summary statistics from the three lipid 340 GWAS of 188,577 individuals obtained from the Global Lipids Genetics Consortium (GLGL)<sup>15</sup>, 341 the MR analysis was performed using the MR Base package<sup>39</sup> and the two-sample MR method <sup>38</sup>. 342

## 343 Integration with PPI Networks

Binary PPIs were extracted from a systematically generated and literature-curated datasets, which 344 in total contain ~58,000 PPIs among 10,690 human proteins<sup>11, 14</sup>. Putatively causal variants from 345 genotyping and gene expression analysis were integrated with PPI networks to assess the extent 346 of potential network perturbations associated with disruption of PPIs or altered expression<sup>9</sup>. 347 Network perturbation information on missense alleles for various lipids-associated genes, which 348 assesses the degree to which a mutant protein exhibits an altered spectrum of PPIs relative to the 349 WT protein and all other mutants<sup>11, 14</sup>, was also included. For proteins without direct (physical) 350 interactions, we use predicted protein-protein interactions from the STRING database to expand 351 the network<sup>40</sup>. 352

## 353 Identifying Candidate Genes

All candidate genes were assessed by each of the each of the following criteria: 1) Does the candidate gene contain a SNP(s) associated with a lipid trait in GWAS ( $p<5x10^{-8}$ ) and is the GWAS SNP(s) is also an eQTL? 2) Is expression of the eQTL-associated gene also associated with the same lipid trait? 3) Are genetic effects on the lipid trait mediated by the expression of the eQTL-associated gene? 4) Does the gene test positive in MR (p<0.05)? 5) Have any interactions with CVD related proteins?

- We then ranked the genes based on how many of the criteria were met and further excluded any genes if the knockout was known to be lethal based on existing literature. Three genes ABCA6,
- *ALDH2*, and *SIDT2* met more than three of these selection criteria and were selected for further
- 363 investigation.

## 364 Validation of Candidate Genes in Animal Models

To test the hypothesis that key genes identified in the LIPIDS networks can be validated in mouse 365 models for the corresponding traits, we obtained KO mouse strains for the three genes identified 366 as having causal effects on HDL cholesterol, LDL cholesterol, and triglycerides, respectively. 367 C57BL/6N-*Abca6*<sup>tm2a(KOMP)Wtsi</sup>/TcpRkorJ, B6Dnk;B6N-Aldh2<sup>tm1a(EUCOMM)Wtsi</sup>/IegRkorJ, and 368 B6:129S5-Sidt2tm1Lex/MmucdRkorJ KO mice were generated at The Jackson Laboratory using 369 sperm or embryos provided by the International Knockout Mouse Consortium and maintained on 370 a C57BL/6NJ genetic background. All animals were housed at The Jackson Laboratory, which is 371 approved by the American Association for Accreditation of Laboratory Animal Care. Animals 372 were kept on a 12-hour (6am-6pm) light/dark cycle with a room temperature between 68 and 72°F, 373 and either fed a chow diet (5K52, LabDiet) or a high-fat diet (TD.06414, Teklad Custom Diet). 374

Cohorts of 20 males and 20 females of both KO strains and C57BL/6NJ control mice were raised on the chow diet. At 12 weeks of age, ten males and ten females from each cohort were switched to the high-fat diet while the other animals continued on the chow diet. Plasma samples were collected at 8, 14, 18, and 22 weeks after a four-hour fast. Total cholesterol, HDL cholesterol, and triglycerides were measured using a Beckman Coulter Synchron CX®5 Delta autoanalyzer. Non-HDL was calculated as the difference between total cholesterol and HDL cholesterol.

At 22 weeks of age, animals were euthanized and their livers were snap-frozen. RNA was 381 isolated from liver tissue using the MagMAX mirVana Total RNA Isolation Kit (ThermoFisher) 382 and the KingFisher Flex purification system (ThermoFisher). Tissues were lysed and homogenized 383 in TRIzol Reagent (ThermoFisher). After the addition of chloroform, the RNA-containing aqueous 384 layer was removed for RNA isolation according to the manufacturer's protocol, beginning with 385 386 the RNA bead binding step. RNA concentration and quality were assessed using the Nanodrop 2000 spectrophotometer (Thermo Scientific) and the RNA 6000 Nano LabChip assay (Agilent 387 Technologies). 388

Libraries were prepared by the Genome Technologies core facility at The Jackson Laboratory 389 using the KAPA Stranded mRNA-Seq Kit (KAPA Biosystems), according to the manufacturer's 390 instructions. Briefly, the protocol entailed isolation of polyA containing mRNA using oligo-dT 391 magnetic beads, RNA fragmentation, first and second-strand cDNA synthesis, ligation of Illumina-392 specific adapters containing a unique barcode sequence for each library, and polymerase chain 393 394 reaction (PCR) amplification. Libraries were checked for quality and concentration using the DNA 1000 LabChip assay (Agilent Technologies) and quantitative PCR (KAPA Biosystems), according 395 to the manufacturer's instructions. A total of 36 liver samples were collected (3 male and 3 female 396 Aldh2 knockout mice, 3 male and 3 female Abca6 knockout mice, and 3 male and 3 female 397 wildtype mice, for each of the two diets). A library was made for each sample followed by pooling 398 of 6 libraries and samples were sequenced by the Genome Technologies core facility at The 399 Jackson Laboratory, 125 bp paired-end on the HiSeq 2500 system (Illumina, Inc.; San Diego, CA) 400 401 using the TruSeq SBS Kit v4 reagents (Illumina, Inc.) with a minimum of 40M reads per sample. A repeated measures two-way ANOVA test with post-hoc pairwise comparison was used to test 402 403 for differentially expressed genes between wild type and knock-out mouse. A significant 404 difference was determined at a false discovery rate < 0.05 to account multiple testing.

## 405 Data availability

The genotype data, gene expression, phenotype data that support the findings from the FHS of this study have been deposited in dbGaP (dbGaP Study Accession: phs000363.v16.p10).

#### 408

#### 409

#### 410 Supplementary Materials

- 411 Fig. S1. The functional analyses of differentially expressed genes generated through IPA.
- 412 Fig.S2. Interaction networks of molecules based on known relationships in the QIAGEN413 Knowledge
- 414 Table S1. Clinical Characteristics of the Framingham Heart Study Participants.
- 415 Table S2. SNPs from Lipids GWAS
- 416 Table S3. GWAS SNPs associated with gene expression(eQTLs) in FHS
- 417 Table S4. Mediation effect of SNPs on lipids through gene expression
- Table S5. CVD proteins and their first-degree interactors from protein-protein interaction
- 419 network
- 420 Table S6. Interactions between CVD proteins
- Table S7. Differentially expressed genes from RNA-Seq after ALDH2 and ABCA6 knockout
- Table S8. Overlap and molecular functions of differentially expressed genes between *Aldh2* and *Abca6* knockout mice
- 424

## 425 **References**

426

4271.Pagidipati NJ and Gaziano TA. Estimating deaths from cardiovascular disease: a review of global428methodologies of mortality measurement. *Circulation*. 2013;127:749-56.

Ross S, D'Mello M, Anand SS, Eikelboom J, Consortium CAD, Stewart AF, Samani NJ, Roberts R
and Pare G. Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian
Bandamination Analysis, Circulation Cardiovascular generation 2015;8:C18, 27

431 Randomization Analysis. *Circulation Cardiovascular genetics*. 2015;8:618-27.

Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP,
 Hopewell JC, Webb TR, Zeng L, Dehghan A, Alver M, Armasu SM, Auro K, Bjonnes A, Chasman DI, Chen S,
 Ford I, Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, Kleber ME, Lau KW,

435 Lu X, Lu Y, Lyytikainen LP, Mihailov E, Morrison AC, Pervjakova N, Qu L, Rose LM, Salfati E, Saxena R,

436 Scholz M, Smith AV, Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, de Vries PS,

437 van Zuydam NR, Anand SS, Bertram L, Beutner F, Dedoussis G, Frossard P, Gauguier D, Goodall AH,

438 Gottesman O, Haber M, Han BG, Huang J, Jalilzadeh S, Kessler T, Konig IR, Lannfelt L, Lieb W, Lind L,

439 Lindgren CM, Lokki ML, Magnusson PK, Mallick NH, Mehra N, Meitinger T, Memon FU, Morris AP,

440 Nieminen MS, Pedersen NL, Peters A, Rallidis LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE,

441 Trompet S, Wang L, Zaman KS, Ardissino D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, Chambers

- JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein SE, Esko T, Feitosa MF, Franco OH,
- 443 Franzosi MG, Granger CB, Gu D, Gudnason V, Hall AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C,
- 444 Hofman A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, Kullo IJ, Lehtimaki T,
- Loos RJF, Melander O, Metspalu A, Marz W, Palmer CN, Perola M, Quertermous T, Rader DJ, Ridker PM,
- 446 Ripatti S, Roberts R, Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, Stewart AF, Stott DJ, Thiery J,
- 447 Zalloua PA, O'Donnell CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann J, Clarke R, Watkins H,
- 448 Kathiresan S, McPherson R, Deloukas P, Schunkert H, Samani NJ and Farrall M. A comprehensive 1,000

Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*.
2015;47:1121-1130.

451 Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes TL, Kanoni S, Willenborg C, 4. 452 Burgess S, Amouyel P, Anand S, Blankenberg S, Boehm BO, Clarke RJ, Collins R, Dedoussis G, Farrall M, 453 Franks PW, Groop L, Hall AS, Hamsten A, Hengstenberg C, Hovingh GK, Ingelsson E, Kathiresan S, Kee F, 454 Konig IR, Kooner J, Lehtimaki T, Marz W, McPherson R, Metspalu A, Nieminen MS, O'Donnell CJ, Palmer 455 CN, Peters A, Perola M, Reilly MP, Ripatti S, Roberts R, Salomaa V, Shah SH, Schreiber S, Siegbahn A, Thorsteinsdottir U, Veronesi G, Wareham N, Willer CJ, Zalloua PA, Erdmann J, Deloukas P, Watkins H, 456 457 Schunkert H, Danesh J, Thompson JR, Samani NJ and Consortium CACD. Genetically determined height 458 and coronary artery disease. N Engl J Med. 2015;372:1608-18. 459 5. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, Gustafsson S, Kanoni S, Ganna A, 460 Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog 461 HM, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, 462 Gurdasani D, Heikkila K, Hypponen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, 463 Kettunen J, Kleber ME, Li X, Luan J, Lyytikainen LP, Magnusson PK, Mangino M, Mihailov E, Montasser 464 ME, Muller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, 465 Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, 466 Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, 467 468 Doney AS, Doring A, Elliott P, Epstein SE, Eyjolfsson GI, Gigante B, Goodarzi MO, Grallert H, Gravito ML, 469 Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones 470 MR, Kaleebu P, Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimaki 471 T, Lin SY, Lindstrom J, Loos RJ, Mach F, McArdle WL, Meisinger C, Mitchell BD, Muller G, Nagaraja R, 472 Narisu N, Nieminen TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, 473 Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, 474 Silander K, Stancakova A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, 475 Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, 476 Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein 477 SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YD, Collins FS, Cooper RS, Danesh 478 J, Dedoussis G, de Faire U, Feranil AB, Ferrieres J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason 479 V, Gyllensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, 480 Humphries SE, Hunt SC, Hveem K, Iribarren C, Jarvelin MR, Jula A, Kahonen M, Kaprio J, Kesaniemi A, 481 Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, 482 Lindgren CM, Martin NG, Marz W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L, 483 Morris AD, Munroe PB, Njolstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, 484 Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PE, Sheu WH, 485 Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, 486 Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolffenbuttel BH, 487 Altshuler D, Ordovas JM, Boerwinkle E, Palmer CN, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, 488 Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Mohlke KL, Ingelsson E, Abecasis GR, 489 Daly MJ, Neale BM and Kathiresan S. Common variants associated with plasma triglycerides and risk for 490 coronary artery disease. Nature genetics. 2013;45:1345-52. 491 6. Rockman MV and Kruglyak L. Genetics of global gene expression. Nature reviews Genetics. 492 2006;7:862-72.

493 7. Weile J, Sun S, Cote AG, Knapp J, Verby M, Mellor JC, Wu Y, Pons C, Wong C, van Lieshout N,

494 Yang F, Tasan M, Tan G, Yang S, Fowler DM, Nussbaum R, Bloom JD, Vidal M, Hill DE, Aloy P and Roth FP.

495 A framework for exhaustively mapping functional missense variants. *Mol Syst Biol*. 2017;13:957.

496 8. Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J and Barabasi AL. Disease
497 networks. Uncovering disease-disease relationships through the incomplete interactome. *Science*.
498 2015;347:1257601.

9. Sharma A, Halu A, Decano JL, Padi M, Liu YY, Prasad RB, Fadista J, Santolini M, Menche J, Weiss
ST, Vidal M, Silverman EK, Aikawa M, Barabasi AL, Groop L and Loscalzo J. Controllability in an islet
specific regulatory network identifies the transcriptional factor NFATC4, which regulates Type 2 Diabetes
associated genes. *NPJ systems biology and applications*. 2018;4:25.

Yao C, Chen BH, Joehanes R, Otlu B, Zhang X, Liu C, Huan T, Tastan O, Cupples LA, Meigs JB, Fox
CS, Freedman JE, Courchesne P, O'Donnell CJ, Munson PJ, Keles S and Levy D. Integromic analysis of
genetic variation and gene expression identifies networks for cardiovascular disease phenotypes. *Circulation*. 2015;131:536-49.

50711.Rolland T, Tasan M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, Yi S, Lemmens I, Fontanillo C,508Mosca R, Kamburov A, Ghiassian SD, Yang X, Ghamsari L, Balcha D, Begg BE, Braun P, Brehme M, Broly

509 MP, Carvunis AR, Convery-Zupan D, Corominas R, Coulombe-Huntington J, Dann E, Dreze M, Dricot A,

510 Fan C, Franzosa E, Gebreab F, Gutierrez BJ, Hardy MF, Jin M, Kang S, Kiros R, Lin GN, Luck K, MacWilliams

511 A, Menche J, Murray RR, Palagi A, Poulin MM, Rambout X, Rasla J, Reichert P, Romero V, Ruyssinck E,

512 Sahalie JM, Scholz A, Shah AA, Sharma A, Shen Y, Spirohn K, Tam S, Tejeda AO, Trigg SA, Twizere JC, Vega

513 K, Walsh J, Cusick ME, Xia Y, Barabasi AL, Iakoucheva LM, Aloy P, De Las Rivas J, Tavernier J, Calderwood 514 MA, Hill DE, Hao T, Roth FP and Vidal M. A proteome-scale map of the human interactome network. *Cell*.

515 2014;159:1212-1226.

516 12. Dalal JJ, Padmanabhan TN, Jain P, Patil S, Vasnawala H and Gulati A. LIPITENSION: Interplay
517 between dyslipidemia and hypertension. *Indian J Endocrinol Metab*. 2012;16:240-5.

Joehanes R, Zhang X, Huan T, Yao C, Ying SX, Nguyen QT, Demirkale CY, Feolo ML, Sharopova NR,
Sturcke A, Schaffer AA, Heard-Costa N, Chen H, Liu PC, Wang R, Woodhouse KA, Tanriverdi K, Freedman
JE, Raghavachari N, Dupuis J, Johnson AD, O'Donnell CJ, Levy D and Munson PJ. Integrated genome-wide
analysis of expression quantitative trait loci aids interpretation of genomic association studies. *Genome biology*. 2017;18:16.

523 14. Luck K, Kim DK, Lambourne L, Spirohn K, Begg BE, Bian W, Brignall R, Cafarelli T, Campos-Laborie 524 FJ, Charloteaux B, Choi D, Cote AG, Daley M, Deimling S, Desbuleux A, Dricot A, Gebbia M, Hardy MF,

525 Kishore N, Knapp JJ, Kovacs IA, Lemmens I, Mee MW, Mellor JC, Pollis C, Pons C, Richardson AD,

526 Schlabach S, Teeking B, Yadav A, Babor M, Balcha D, Basha O, Bowman-Colin C, Chin SF, Choi SG,

527 Colabella C, Coppin G, D'Amata C, De Ridder D, De Rouck S, Duran-Frigola M, Ennajdaoui H, Goebels F,

528 Goehring L, Gopal A, Haddad G, Hatchi E, Helmy M, Jacob Y, Kassa Y, Landini S, Li R, van Lieshout N,

529 MacWilliams A, Markey D, Paulson JN, Rangarajan S, Rasla J, Rayhan A, Rolland T, San-Miguel A, Shen Y,

530 Sheykhkarimli D, Sheynkman GM, Simonovsky E, Tasan M, Tejeda A, Tropepe V, Twizere JC, Wang Y,

531 Weatheritt RJ, Weile J, Xia Y, Yang X, Yeger-Lotem E, Zhong Q, Aloy P, Bader GD, De Las Rivas J, Gaudet S,

Hao T, Rak J, Tavernier J, Hill DE, Vidal M, Roth FP and Calderwood MA. A reference map of the human
binary protein interactome. *Nature*. 2020;580:402-408.

15. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J,

535 Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Do R,

536 Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF,

537 Gurdasani D, Heikkila K, Hypponen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M,

538 Kettunen J, Kleber ME, Li X, Luan J, Lyytikainen LP, Magnusson PKE, Mangino M, Mihailov E, Montasser

539 ME, Muller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R,

540 Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM,

541 Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D,

Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M,

543 Doney ASF, Doring A, Elliott P, Epstein SE, Ingi Eyjolfsson G, Gigante B, Goodarzi MO, Grallert H, Gravito

544 ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, 545 Jones MR, Kaleebu P, Kastelein JJP, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, 546 Lehtimaki T, Lin SY, Lindstrom J, Loos RJF, Mach F, McArdle WL, Meisinger C, Mitchell BD, Muller G, 547 Nagaraja R, Narisu N, Nieminen TVM, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla 548 C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, 549 Seeley J, Silander K, Stancakova A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, 550 Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein 551 552 SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YI, Collins FS, Cooper RS, Danesh 553 J, Dedoussis G, de Faire U, Feranil AB, Ferrieres J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason 554 V, Gyllensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, 555 Humphries SE, Hunt SC, Hveem K, Iribarren C, Jarvelin MR, Jula A, Kahonen M, Kaprio J, Kesaniemi A, 556 Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, 557 Lindgren CM, Martin NG, Marz W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L, 558 Morris AD, Munroe PB, Njolstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, 559 Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PEH, Sheu WH, 560 Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, 561 Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolffenbuttel BHR, 562 Ordovas JM, Boerwinkle E, Palmer CNA, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, 563 Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, Abecasis 564 GR and Global Lipids Genetics C. Discovery and refinement of loci associated with lipid levels. Nature 565 genetics. 2013;45:1274-1283. 566 16. Chen X, Gu X and Zhang H. Sidt2 regulates hepatocellular lipid metabolism through autophagy. J 567 Lipid Res. 2018;59:404-415. 568 17. Meng Y, Wang L and Ling L. Changes of lysosomal membrane permeabilization and lipid 569 metabolism in sidt2 deficient mice. Exp Ther Med. 2018;16:246-252. 570 Dean M and Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in 18. vertebrates. Annu Rev Genomics Hum Genet. 2005;6:123-42. 571 Kaminski WE, Wenzel JJ, Piehler A, Langmann T and Schmitz G. ABCA6, a novel a subclass ABC 572 19. 573 transporter. Biochemical and biophysical research communications. 2001;285:1295-301. 574 Pohl A, Devaux PF and Herrmann A. Function of prokaryotic and eukaryotic ABC proteins in lipid 20. 575 transport. Biochimica et biophysica acta. 2005;1733:29-52. 576 Wada M, Daimon M, Emi M, Iijima H, Sato H, Koyano S, Tajima K, Kawanami T, Kurita K, Hunt SC, 21. 577 Hopkins PN, Kubota I, Kawata S and Kato T. Genetic association between aldehyde dehydrogenase 2 578 (ALDH2) variation and high-density lipoprotein cholesterol (HDL-C) among non-drinkers in two large 579 population samples in Japan. J Atheroscler Thromb. 2008;15:179-84. 580 Gao J, Zhang Y, Yu C, Tan F and Wang L. Spontaneous nonalcoholic fatty liver disease and ER 22. 581 stress in Sidt2 deficiency mice. Biochemical and biophysical research communications. 2016;476:326-582 332. 583 23. Mendez-Acevedo KM, Valdes VJ, Asanov A and Vaca L. A novel family of mammalian 584 transmembrane proteins involved in cholesterol transport. Scientific reports. 2017;7:7450. 585 24. Kramer A, Green J, Pollard J, Jr. and Tugendreich S. Causal analysis approaches in Ingenuity 586 Pathway Analysis. Bioinformatics. 2014;30:523-30. 587 Ongen H, Brown AA, Delaneau O, Panousis NI, Nica AC, Consortium GT and Dermitzakis ET. 25. 588 Estimating the causal tissues for complex traits and diseases. Nature genetics. 2017;49:1676-1683. 589 Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H, Kuperwasser 26. 590 N, Ruda VM, Pirruccello JP, Muchmore B, Prokunina-Olsson L, Hall JL, Schadt EE, Morales CR, Lund-Katz

591 S, Phillips MC, Wong J, Cantley W, Racie T, Ejebe KG, Orho-Melander M, Melander O, Koteliansky V,

592 Fitzgerald K, Krauss RM, Cowan CA, Kathiresan S and Rader DJ. From noncoding variant to phenotype via 593 SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714-9. 594 Atanasovska B, Kumar V, Fu J, Wijmenga C and Hofker MH. GWAS as a Driver of Gene Discovery 27. 595 in Cardiometabolic Diseases. Trends in endocrinology and metabolism: TEM. 2015;26:722-732. 596 Jones NS, Watson KQ and Rebeck GW. Metabolic Disturbances of a High-Fat Diet Are Dependent 28. 597 on APOE Genotype and Sex. eNeuro. 2019;6. 598 Yadav A, Vidal M and Luck K. Precision medicine - networks to the rescue. Curr Opin Biotechnol. 29. 599 2020;63:177-189. 600 30. Oppenheimer GM. Becoming the Framingham Study 1947-1950. Am J Public Health. 601 2005;95:602-10. 602 31. Dawber TR, Meadors GF and Moore FE, Jr. Epidemiological approaches to heart disease: the 603 Framingham Study. American journal of public health and the nation's health. 1951;41:279-81. 604 Feinleib M, Kannel WB, Garrison RJ, McNamara PM and Castelli WP. The Framingham Offspring 32. 605 Study. Design and preliminary data. Preventive medicine. 1975;4:518-25. 606 33. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D'Agostino RB, Sr., Fox CS, 607 Larson MG, Murabito JM, O'Donnell CJ, Vasan RS, Wolf PA and Levy D. The Third Generation Cohort of 608 the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial 609 examination. Am J Epidemiol. 2007;165:1328-35. 610 Benjamin AM, Suchindran S, Pearce K, Rowell J, Lien LF, Guyton JR and McCarthy JJ. Gene by sex 34. 611 interaction for measures of obesity in the framingham heart study. J Obes. 2011;2011:329038. 612 Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP. Summaries of Affymetrix 35. GeneChip probe level data. Nucleic acids research. 2003;31:e15. 613 614 36. Stegle O, Parts L, Piipari M, Winn J and Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc. 615 616 2012;7:500-7. 617 37. Imai K, Keele L and Tingley D. A general approach to causal mediation analysis. Psychological 618 methods. 2010;15:309-34. 619 Hartwig FP, Davies NM, Hemani G and Davey Smith G. Two-sample Mendelian randomization: 38. 620 avoiding the downsides of a powerful, widely applicable but potentially fallible technique. International 621 journal of epidemiology. 2017. 622 Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, 39. 623 Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith 624 G, Gaunt TR and Haycock PC. The MR-Base platform supports systematic causal inference across the 625 human phenome. Elife. 2018;7. 626 40. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, 627 Morris JH, Bork P, Jensen LJ and Mering CV. STRING v11: protein-protein association networks with 628 increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic 629 Acids Res. 2019;47:D607-D613. 630 631 632 633 634 635 Acknowledgments: We gratefully acknowledge the contribution of the Reproductive Science, Histopathology, and Genome Technologies Services at The Jackson Laboratory for expert 636 assistance with the work described in this publication. Funding: The Framingham Heart Study is 637

funded by National Institutes of Health contract N01-HC-25195. The analytical component for this investigation was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (D. Levy, Principal Investigator). The laboratory work of this project was funded by American Heart Association (AHA) Cardiovascular Genome-Phenome Study (CVGPS) grant 15CVGPS23430000. Author contributions: Conceptualization, C.Y. and D.L. Methodology and data analysis, C.Y. Mouse knockout experiments, H.S., Y.T., R.K. Protein interaction network, T.H., W.B., D.E.H, M.V. Writing, C.Y., R.K., D.L. Competing interests: No competing interests to declare for all authors. Data and materials availability: The SNP, gene expression and protein phenotype data that Support the findings from the FHS of this study have been deposited in dbGaP (dbGaP Study Accession: phs000363.v16.p10). **Figures**: **Figure 1. Study Design** 





- per diet group. Asterisk indicates a significant difference (P<0.05) between knockout and wildtype
- 689 at the specific time point.
- 690 Female



691

693 Male



## 699 Figure 3. Comparison between *Aldh2* knockout (solid line) and wildtype (dotted line) mice

700 in females and males on regular chow and high-fat diet. Ten mice for each genotype and sex

per diet group. Asterisk indicates a significant difference (P < 0.05) between knockout and wildtype

- at the specific time point.
- 703 Female



- 717
- 718
- 719

#### 721 Male





## 730 Figure 4. Comparison between *Sidt2* knockout (solid line) and wildtype (dotted line) mice in

731 males and females on regular chow and high-fat diet. Ten mice for each genotype and sex per

diet group. Asterisk indicates a significant difference (P < 0.05) between knockout and wildtype at

- the specific time point.
- 734 Female



736 Male



# 743 Table 1 . MR tests for candidate genes

Exposure	Outcome	Instrumental	Beta	SE	P Value
DOCK7	HDL cholesterol	rs10889354	0.22	0.0821	0.0067
	LDL cholesterol	rs10889354	0.75	0.086	2.22E-18
	Triglycerides	rs10889354	1.15	0.078	1.56E-48
TAGLN	HDL cholesterol	rs3736120	-0.18	0.067	0.0091
	LDL cholesterol	rs3736120	-0.14	0.074	0.064
	Triglycerides	rs3736120	-0.34	0.066	2.90E-07
SIDT2	HDL cholesterol	rs12420127	0.27	0.11	0.013
	LDL cholesterol	rs12420127	0.32	0.12	0.0065
	Triglycerides	rs12420127	0.32	0.11	0.0027
ALDH2	HDL cholesterol	rs10744777	0.20	0.09	0.017
	LDL cholesterol	rs10744777	0.49	0.093	1.28E-07
	Triglycerides	rs10744777	-0.23	0.083	0.0056
SLC44A4	HDL cholesterol	rs535586	0.079	0.055	0.15
	LDL cholesterol	rs535586	-0.23	0.059	0.00011
	Triglycerides	rs535586	-0.38	0.054	2.56E-12
ABCA6	HDL cholesterol	rs918167	0.10	0.093	0.27
	LDL cholesterol	rs918167	0.061	0.10	0.55
	Triglycerides	rs918167	-0.16	0.091	0.079
ATG4C	HDL cholesterol	rs7540030	0.14	0.19	0.46
	LDL cholesterol	rs7540030	0.17	0.20	0.40
	Triglycerides	rs7540030	0.10	0.18	0.56

# 745 Table 2. Criteria of candidate gene selection

	Causal effects (MR P<0.05)	Novelty	Availability of knockout mice	Associated with CVD- proteins in PPI network
DOCK7	3 lipids traits	No	Yes	Yes
TAGLN	2 lipids traits	No	Yes	Yes
SIDT2	2 lipids traits	No	Yes	Yes
ALDH2	3 lipids traits	Yes	Yes	Yes
SLC44A4	2 lipids traits	Yes	No	No
ABCA6	0 lipids traits	Yes	Yes	Yes
ATG4C	0 lipids traits	Yes	Yes	No